PERSONAL PRACTICE

Autosomal recessive osteopetrosis: diagnosis, management, and outcome

C J Wilson, A Vellodi

Metabolic Unit, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK

C J Wilson

Biochemistry, Endocrinology, and Metabolism Unit, Institute of Child Health, London, UK
A Vellodi

Correspondence to:
Dr Wilson
callumjwilson@yahoo.com

Accepted 18 July 2000

Figure 1 Typical osteopetrosis changes of increased bone density, loss of the normal corticomedullary differentiation, and a bone-in-bone appearance of the metacarpals.

Autosomal recessive “malignant” osteopetrosis is a rare congenital disorder of bone resorption. It is caused by the failure of osteoclasts to resorb immature bone.^{1–3} This leads to abnormal bone marrow cavity formation and clinically to the signs and symptoms of bone marrow failure. Impaired bone remodelling causes bony narrowing of the cranial nerve foramina which results in cranial nerve, especially optic nerve, compression.² Pathologically there is a persistence of the primary spongiosa characterised by cores of calcified cartilage within bone. Abnormal remodelling of primary, woven bone to lamellar bone results in “brittle” bone that is prone to fracture.^{1,2} Thus fractures, visual impairment, and bone marrow failure are the classical feature of the disease.⁴ Osteopetrosis has been reported in most ethnic groups although as the disease is very rare it is more frequently seen in ethnic groups where consanguinity is common. Infantile onset osteopetrosis should also be distinguished from the much milder autosomal dominant adult disease and the carbonic anhydrase II deficiency syndrome which is associated with renal tubular acidosis and less severe osteopetrosis.^{5,6}

Presentation

Affected children usually present within the first year of life and frequently within the first three months.^{4,7–9} Parental concern regarding the child’s vision is the most common presenting complaint. Failure to achieve normal visual milestones, roving eye movements, and/or squint are often reported. Other presentations include failure to thrive and recurrent infection, both secondary to the underlying anaemia and bone marrow involvement. Hypocalcaemic seizures, excessive bruising, fractures, nasal congestion, and an abnormal craniofacial appearance are less common presenting complaints.^{4,7–9} These symptoms are non-specific and while hepatosplenomegaly is invariably present at an early age this may be missed and because of the disease rarity a correct clinical diagnosis is often not initially made. Frequently it is the distinctive sclerotic bony changes seen on a serendipitously performed x ray that alerts the clinician (fig 1). If radiological appearances are supportive and the child has features of anaemia with compensatory erythropoietic hepatosplenomegaly and/or visual impairment then the diagnosis is highly likely. A skeletal survey should be

performed and reviewed by an experienced paediatric radiologist to confirm the diagnosis. There are a large number of, individually rare, genetic conditions associated with osteosclerosis or osteopetrosis. Only a small number of these are associated with anaemia and visual impairment.¹⁰ Dysosteosclerosis is a very rare condition which can present with a very similar phenotype to osteopetrosis. These patients are not usually anaemic however and while the initial x ray changes may be indistinguishable from osteopetrosis they later develop the characteristic irregularly coarse submetaphyseal trabecular pattern.^{11,12}

A bone biopsy is not usually required, although if the initial diagnosis is unclear or the child’s clinical progress varies significantly from the established phenotype then a biopsy may prove beneficial.

Management

Initial management should focus on establishing the severity and extent of the disease.

HAEMATOLOGY

The majority of patients, because of a failure of bone marrow development, are anaemic and many become transfusion dependent. Transfusion dependency prior to 3 months of age is a sign of severe disease and thus a poor prognostic sign.^{4,9,13} These children often have massive compensatory extramedullary haemopoietic hepatosplenomegaly (fig 2). While most transfusion dependent patients remain so, some acquire haemopoietic competence, probably as a result of extramedullary recruitment or perhaps bone marrow recrudescence.⁹ Because of the possibility of future bone marrow transplantation, blood should ideally be taken for tissue typing prior to the initial transfusion.

RECURRENT INFECTION

The generation of superoxide by peripheral blood leucocytes is defective in patients with osteopetrosis.^{14,15} This, along with the anaemia, poor nutrition, recurrent hospital admissions, and the frequent ear, nose, and throat complications, results in a greatly increased susceptibility to infections. This can be especially debilitating in the young child. The infections are usually of viral aetiology, most commonly affect the respiratory tract, and are often prolonged. Infections, especially pneumonia and septicaemia, are a common cause of

Figure 2 Bone marrow scintigraphy of an osteopetrosis patient, showing almost complete absence of bone marrow in the long bones and pelvis, although with residual activity still apparent in the skull. The compensatory extramedullary haematopoiesis in the massively enlarged liver and spleen is also shown.

death.^{4 7-9 13} In infancy this infection risk should be viewed as an indication for bone marrow transplantation (BMT).

VISION

The majority of children with osteopetrosis develop some degree of visual impairment. It is essential that all patients are assessed soon after the initial diagnosis and at regular intervals by a paediatric ophthalmologist. Clinically there is often optic atrophy although the retina is otherwise unremarkable. The visual evoked potentials (VEPs) are the most useful way of monitoring optic nerve involvement while an electroretinogram may help rule out associated neurological disease.¹⁶ The visual loss, caused by bony encroachment of the optic nerve at the level optic foramina, is progressive and almost always occurs within the first year of life.^{4 9 13 16} Severely affected children may show absent or severely attenuated VEPs within the first three months, and in some this is apparent at birth. Because the rate of visual deterioration tends to

plateau after 18 months to two years, some children, despite poor early neurophysiological findings, maintain a degree of visual acuity into later childhood.

Unfortunately an improvement in visual status is unlikely, despite treatment.^{9 13 16} Optic nerve decompression is a hazardous procedure and reports suggest success only in mildly affected older children.^{4 17 18} With younger children the focus should be on obtaining a BMT, with the expectation being the preservation of existing sight rather than a reversal of the disease process. Children with intact vision must be regarded as urgent priority in regard to BMT waiting lists.

HEARING

Hearing is less commonly affected than vision, with approximately a third of patients having some degree of hearing loss.^{4 7-9 19} The impairment usually manifests within the first year of life. The pathology of the deafness is unclear but is probably secondary to a combination of bony compression of the nerve, sclerosis of the middle ear ossicles, and/or chronic middle ear effusion. Early insertion of ventilatory "grommet" tubes should be considered.

FAILURE TO THRIVE

Failure to thrive is seen in many osteopetrotic children and is a result of the chronic anaemia, feeding problems caused by bulbar nerve involvement, nasal congestion, and recurrent infections.^{4 9 19 20} Many children require nasal gastric feeds to improve energy intake. This procedure may be difficult as osteopetrotic children often have choanal narrowing, nasal congestion, and obstructive sleep apnoea, and will not tolerate nasogastric tubes.¹⁹ The alternative of a gastrostomy carries the risk of infection in those patients who may be candidates for BMT.

OTHER NEUROLOGICAL DISORDERS

As well as II and VIII, other cranial nerves may be involved in osteopetrosis. This is again a result of bony encroachment, but the manifestations are usually relatively mild and thus less obvious.^{9 21 22} Children may have some paucity of facial expression or difficulties with feeding and swallowing. Less commonly there is neurophysiological evidence of involvement of the peripheral motor nerves, probably caused by bony pressure at the nerve root.⁹

Children with osteopetrosis have multiple handicaps and thus an accurate assessment of their cognitive function is difficult. Developmental delay, if present, is usually consistent with the extent of physical and visual impairment, and the severity of chronic illness the child has suffered.^{13 23}

Children with classical congenital osteopetrosis should not have central nervous system involvement. Significant developmental delay or regression, unexplained seizures, retinopathy, or radiological brain changes should alert the clinician to the rare but well reported neurodegenerative condition that can affect patients.^{4 9 24-27} This association between osteopetrosis and neurodegeneration probably encompasses a heterogeneous group of diseases. They are often

rapidly progressive and as they generally carry a poor prognosis the finding of CNS involvement may constitute a contraindication to BMT. It is thus mandatory to perform a thorough clinical, radiological (magnetic resonance imaging of the brain), and neurophysiological examination on all osteopetrotic patients.

CARDIAC DISORDERS

While not reported in the literature we know of four patients who had acute pulmonary hypertension and whom have subsequently died. Another had pulmonary valve stenosis and regurgitation with post-valvular pulmonary dilatation. It would seem prudent therefore to perform a cardiac assessment in all patients.

BIOCHEMISTRY

Complications of hypocalcaemia (especially pre-BMT) and hypercalcaemia (post-BMT) are common. Both can be difficult to control. The vitamin D analogues and calcium supplements used to treat the former may make the latter more likely post-BMT and the clinician should be careful not to "over treat".⁹ Bisphosphonates, phosphate infusions, and calcitonin may be useful in the severe recalcitrant hypercalcaemia sometimes seen post-transplantation.²⁸

ORTHOPAEDIC DISORDERS

Fractures are common and are one of the classical features of osteopetrosis. The susceptibility is variable and in some children recurrent fractures are the most debilitating part of the disease.^{4 7-9 13} They tend to occur only after moderate trauma and are thus rare in infancy. The long bones are most frequently affected.^{29 30} Patients seem to be susceptible to fractures for some time after successful BMT. Most fractures can be treated with conservative closed techniques and in most cases the fracture heals normally but with some delay. Open treatment with fixation can be technically demanding because of the sclerotic bone. In particular intermedullary rod fixation of femur fractures is extremely difficult because of the bony obliteration of the normal marrow cavity. Problems with bleeding and infections are frequently encountered because of the underlying disease.^{29 30} Because of these problems and the overall prevalence of fractures, optimal pain management is essential in the management of affected children.

Children with osteopetrosis often have an abnormal head shape. Macrocephaly and frontal bossing are common, especially in early childhood.^{31 32} Craniosynostosis may be a problem in both the transplanted and non-transplanted patient. Regular measurement of head circumference and a computed tomography scan with surgical referral if necessary is suggested. Surgical vault release however may result in significant intracranial perioperative bleeding, probably secondary to underlying cerebral venous obstruction at the level of the exit foramina.⁹

Children frequently have dental problems; failure of tooth eruption, recurrent caries, and abnormal dentinogenesis have all been reported.^{7-9 33}

MEDICAL TREATMENT

Corticosteroids, high dose calcitriol, and interferon γ have all been reported to be helpful in the treatment of osteopetrosis.³⁴⁻³⁸ The initial promise of steroids and calcitriol has proved unwarranted although there may be some initial short term benefit.^{38 39} Key *et al* reported very encouraging results with recombinant human interferon γ -1b (1.5 μ g/kg, three times per week).³⁸ Increased bone resorption and haematopoiesis and improved leucocyte function was seen in the small number of patients studied. The study group however had a mean age of 4 years and thus they were in a relatively stable period of the disease. Most importantly there was no control group and follow up was for only 18 months. More studies of interferon γ are warranted and awaited. Our experience with the drug in the early onset severely affected group of patients is disappointing although in the older infant it may help reduce infection and improve bone resorption.

PALLIATIVE CARE

In some patients, because of the severity of their disease, aggressive treatment is not warranted and palliative care is indicated. Adequate pain relief is essential and the assistance of the local palliative care team and support services should be sought.

Outcome

NATURAL HISTORY

Osteopetrosis has a high mortality rate in the first two years of life. Children with severe disease, that is, those with significant visual and haematological impairment before the age of 3 months, frequently die in infancy.^{4 7-9 13} The cause of death is often bone marrow failure and overwhelming infection. It is unlikely that medical therapy significantly alters the natural history of the disease in this group of patients and urgent BMT should be sought. Conversely children who are not transfusion dependent and are alive at 2 years of life form a relatively favourable prognostic group. While orthopaedic complications continue to be a problem and there is usually significant visual impairment, the mortality rate is low and, in the absence of a suitable bone marrow donor, treatment with interferon γ or high dose calcitriol may be warranted. Further studies of the long term prognosis in this group of children are needed. Reports of adults with autosomal recessive osteopetrosis are rare.

BONE MARROW TRANSPLANTATION

Bone marrow transplantation is the only treatment that has been proven to significantly alter the course of disease. While successful recipients may continue to have minor orthopaedic and dental problems and their vision rarely significantly improves, their haemopoietic potential is restored and the long term prognosis is favourable. The success of engraftment and thus outcome is very dependent however on the availability of a suitable HLA match. In 1994, Gerritsen *et al* reported a 79% five year disease free survival in 19 patients with a HLA

Table 1 Investigation of the new osteopetrotic patient

Full blood count, urea and electrolytes, Ca^{2+} , PO_4^{2-} , blood gas
Feeding assessment
Skeletal survey including skull views
Tissue typing of child and family
Ophthalmological assessment including VEPs and electroretinography
Hearing assessment
Neurological/developmental assessment
Cardiac assessment
Consider magnetic resonance imaging of brain
Consider computed tomography of optic foramina

identical sibling donor. Recipients of non-genotypically identical grafts had significantly worse results with only a 13% five year disease free survival in those receiving marrow from an HLA haplotype mismatched related donor.¹³ BMT should thus be reserved for those cases where there is at least a phenotypical HLA identical match available. Bone marrow immunoscintigraphy, by showing the extent of marrow recrudescence, may be useful in monitoring the effectiveness of therapy after transplantation.⁴⁰

GENETICS

Infantile osteopetrosis is a heterogeneous disease and a number of genetic loci are likely.⁴¹ Recently mutations in the gene coding for an osteoclast specific vacuolar pump have been found in a subset of affected children.⁴² The near future will see other genes being mapped, cloned, and mutational analysis hopefully made available. Careful informed genetic counselling of families is needed to take advantage of these recent advances.

Children with osteopetrosis require a multi-disciplinary approach. As well as the paediatrician, a feeding specialist, ophthalmologist, audiologist, dentist, and the bone marrow transplant team should be involved. Initial management should focus on establishing the severity of the illness with emphasis on the neurological, haematological, and feeding status of the child (table 1). Tissue typing should be arranged and based on the availability of a suitable donor BMT performed as soon as is practical. Urgent status should be reserved for those children with intact vision and those with severe disease. Whether or not a BMT is performed, continuing management should focus on meeting the child's educational, social, and medical needs.

- 1 Helfrich MA, Aronson DC, Everts V, *et al.* Morphologic features of bone in human osteopetrosis. *Bone* 1991;12:411-19.
- 2 Felix R, Hofstetter W, Cecchini MG. Recent developments in the understanding of osteopetrosis. *Eur J Endocrinol* 1996;134:143-56.
- 3 Flanagan AM, Sarma U, Steward CG, Vellodi A, Horton MA. Study of the nonresorptive phenotype of osteoclast-like cells from patients with malignant osteopetrosis: a new approach to investigating pathogenesis. *J Bone Miner Res* 2000;15:352-60.
- 4 Gerritsen EJ, Vossen JM, van Loo IH, *et al.* Autosomal recessive osteopetrosis: variability of findings at diagnosis and during the natural course. *Paediatrics* 1994;93:247-53.
- 5 Benichou OD, Laredo JD, de Veinejoul MC. Type II autosomal dominant osteopetrosis: clinical and radiological manifestations in 42 patients. *Bone* 2000;26:87-93.
- 6 Johnston CC, Lavy N, Lord T, Vellios F, Merriitt AD, Deiss WP. Osteopetrosis: a clinical, genetic, metabolic, and morphological study of the dominantly inherited benign form. *Medicine* 1968;47:149-67.
- 7 Loria-Cortes R, Quesada-Calvo E, Cordero-Chaverri C. Osteopetrosis in children: a report of 26 cases. *J Pediatr* 1977;91:43-7.

- 8 Abdel Al YK, Shabani IS, Lubani MM, *et al.* Autosomal recessive osteopetrosis in Arab children. *Ann Trop Paediatr* 1994;14:59-64.
- 9 Wilson CJ, Vellodi A. Unpublished data.
- 10 Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000. <http://www.ncbi.nlm.nih.gov/omim/>
- 11 Houston CS, Gerrard JW, Ives EJ. Dysosteosclerosis. *Am J Roentgenol* 1978;130:988-91.
- 12 Chitayat D, Silver K, Azouz EM. Skeletal dysplasia, intracerebral calcifications, optic atrophy, hearing impairment, and mental retardation: nosology of dysosteosclerosis. *Am J Med Genet* 1992;43:517-23.
- 13 Gerritsen EJA, Vossen JM, Fasth A, *et al.* Bone marrow transplantation for osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. *J Pediatr* 1994;125:896-902.
- 14 Beard CJ, Key LL, Newberger PE, *et al.* Neutrophil defect associated with malignant infantile osteopetrosis. *J Lab Clin Med* 1986;108:498-505.
- 15 Reeves JD, August CS, Humbert JR, Weston WL. Host defense in infantile osteopetrosis. *Pediatrics* 1979;64:202-6.
- 16 Thompson DA, Kriss A, Taylor D, *et al.* Early VEP and ERG evidence of visual dysfunction in autosomal recessive osteopetrosis. *Neuropediatrics* 1998;29:137-44.
- 17 Al-Mefty O, Fox JL, Al-Rodhan N, Dew JH. Optic nerve decompression in osteopetrosis. *J Neurosurg* 1988;68:80-4.
- 18 Haines SJ, Erickson DL, Wirtshafter JD. Optic nerve decompression for osteopetrosis in early childhood. *Neurosurgery* 1988;23:470-5.
- 19 Stocks RM, Wang WC, Thompson JW, Stocks MC, Horwitz EM. Malignant infantile osteopetrosis: otolaryngological complications and management. *Arch Otolaryngol Head Neck Surg* 1988;114:689-94.
- 20 Williams R, Wang W. Managing osteopetrosis in children: a nutritional challenge. *J Am Diet Assoc* 1996;96:172-5.
- 21 Dort JC, Pollak A, Fisch U. Facial nerve dysfunction in osteopetrosis. *Laryngoscope* 1994;104:517.
- 22 Bajaj S, Gupta SC, Nigam NK. Osteopetrosis with bilateral facial nerve palsy. *J Assoc Physicians India* 1986;34:529-30.
- 23 Charles JM, Key LL. Developmental spectrum of children with congenital osteopetrosis. *J Pediatr* 1998;132:371-4.
- 24 Ambler MW, Trice J, Grauerholz J, O'Shea PA. Infantile osteopetrosis and neuroal storage disease. *Neurology* 1983;33:437-41.
- 25 Jagadaha V, Halliday WC, Becker LE, Hinton D. The association of infantile osteopetrosis and neuronal storage disease in two brothers. *Acta Neuropathol* 1988;75:233-40.
- 26 Rees H, Ang LC, Casey R, George DH. Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. *Pediatr Neurol* 1995;22:321-7.
- 27 Abinun M, Newson T, Rowe PW, Flood TJ, Cant AJ. Importance of neurological assessment before marrow transplantation for osteopetrosis. *Arch Dis Child* 1999;80:273-4.
- 28 Rawlinson PSM, Green RHA, Coggins AM, Boyle AM, Gibson BES. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation. *Arch Dis Child* 1991;66:638-9.
- 29 Armstrong DG, Newfield JJ, Gillespie R. Orthopaedic management of osteopetrosis: results of a survey and a review of the literature. *J Pediatr Orthop* 1999;19:122-32.
- 30 Campbell RM. Problem injuries in unique conditions of the musculoskeletal system. In: Rockwood CA, Wilkins KE, Beaty JH, eds. *Fractures in children*, 4th edn. Philadelphia: Lippincott Raven, 1996:184.
- 31 Elster AD, Theros EG, Key LL, Chen MY. Cranial imaging in osteopetrosis. Part I. Facial bones and calvarium. *Radiology* 1992;183:129-35.
- 32 Elster AD, Theros EG, Key LL, Chen MY. Cranial imaging in osteopetrosis. Part II. Skull base and brain. *Radiology* 1992;183:137-44.
- 33 Droz-Desprez D, Azou C, Bordigoni P, Bonnaure-Mallet M. Infantile osteopetrosis: a case report on dental findings. *J Oral Pathol Med* 1992;21:422-5.
- 34 Reeves JD, Huffer WE, August CS, Hathaway WE, Koerper M, Walters CE. The hematopoietic effects of prednisone therapy in four infants with osteopetrosis. *Pediatrics* 1979;64:202-6.
- 35 van Lie Peters EM, Aronsun DC, Everts V, Dooren LJ. Megadose methylprednisolone treatment for malignant osteopetrosis. *Eur J Pediatr* 1994;154:779-80.
- 36 Key LL, Carnes D, Cole S, *et al.* Treatment of congenital osteopetrosis with high dose calcitriol. *N Engl J Med* 1984;310:409-15.
- 37 Key LL, Ries WL, Rodriguiz RM, Hatcher HC. Recombinant human interferon gamma therapy for osteopetrosis. *J Pediatr* 1992;121:119-24.
- 38 Key LL, Rodriguiz RM, Willi SM, *et al.* Long term treatment of osteopetrosis with recombinant human interferon. *N Engl J Med* 1995;332:1594-9.
- 39 van Lie Peters EM, Aronsun DC, Everts V, Dooren LJ. Failure of calcitriol treatment in a patient with malignant osteopetrosis. *Eur J Pediatr* 1993;152:818-21.
- 40 Thelen MH, Eschmann SM, Moll-Kotowski M, Dopfer R, Bares R. Bone marrow scintigraphy with technetium-99m anti-NCA-95 to monitor therapy in malignant osteopetrosis. *J Nucl Med* 1998;39:1033-5.
- 41 Flanagan AM. Unpublished data.
- 42 Frattini A, Orchard PJ, Sobacchi C, *et al.* Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. *Nat Genet* 2000;25:343-6.